Yu-Fei Yang

Prolonged molecular control during intermittent reduced‐intensity blinatumomab maintenance in a transplant‐ineligible patient with Philadelphia chromosome‐positive acute lymphoblastic leukaemia and IKZF1 deletion

Abstract Objectives Long‐term disease control in transplant‐ineligible patients with high‐risk Philadelphia chromosome‐positive acute lymphoblastic leukaemia (Ph+ ALL) remains difficult, particularly when adverse genetic lesions and acquired kinase domain mutations coexist. Methods Clinical, cytogenetic and molecular r...